Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

NYSE ENZ opened at $0.33 on Friday. Enzo Biochem has a 52-week low of $0.25 and a 52-week high of $1.28. The business’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.63.

Enzo Biochem (NYSE:ENZ) last released its quarterly earnings results on Monday, March 17th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%. The company had revenue of $7.33 million for the quarter.

Hedge Funds Weigh In On Enzo Biochem

A number of hedge funds and other institutional investors have recently made changes to their positions in ENZ. Mink Brook Asset Management LLC purchased a new stake in Enzo Biochem in the 4th quarter valued at approximately $577,000. Wittenberg Investment Management Inc. boosted its holdings in Enzo Biochem by 46.2% in the 1st quarter. Wittenberg Investment Management Inc. now owns 274,095 shares of the medical research company’s stock valued at $101,000 after purchasing an additional 86,558 shares in the last quarter. Lepercq De Neuflize Asset Management LLC boosted its holdings in Enzo Biochem by 27.1% in the 1st quarter. Lepercq De Neuflize Asset Management LLC now owns 156,303 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 33,303 shares in the last quarter. Lepercq Multi Asset Fund purchased a new stake in Enzo Biochem in the 4th quarter valued at approximately $88,000. Finally, Virtu Financial LLC purchased a new stake in Enzo Biochem in the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.